Last reviewed · How we verify
NCT03298009: Canacardia
Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)
NA trial testing Canagliflozin 100mg in Type2 Diabetes. Withdrawn.
30 June 2018
Quick facts
| Lead sponsor | Université de Sherbrooke |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | basic science |
| Start date | 1 May 2018 |
| Primary completion | 30 June 2018 |
| Estimated completion | 30 June 2018 |
Drugs / interventions tested
- Canagliflozin 100mg — full drug profile →
- Placebo oral capsule
- PET imaging
Conditions studied
- Type2 Diabetes — all drugs for Type2 Diabetes →
- Heart Failure — all drugs for Heart Failure →
Sponsor
Université de Sherbrooke — full company profile →
Who can join
Adults 18 to 75, any sex, with Type2 Diabetes or Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It is a mechanistic proof-of-concept study to demonstrate how SGLT-2 inhibitors (Canagliflozin) may have a beneficial role on cardiac energetic efficiency. Patients with type 2 diabetes and with HF diagnosed for at least 3 months will be selected. The participants will be randomized to a double-blind, crossover 2-week placebo vs. Cana 100 mg once daily, an interventional trial with a one-month washout period in between. At the term of the two-week placebo and canagliflozin treatment periods (visits 2 and 4), each participant will undergo an identical postprandial metabolic study with positron emission tomography (PET) and stable isotopic tracer methods.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03298009
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Canagliflozin 100mg
Trials testing the same drug.
- NCT06858436 — SGLT2 Inhibitor Utilization Re-perfusion Therapy · Phase 4 · not yet recruiting
- NCT05764811 — SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity · NA · completed
Other recruiting trials for Type2 Diabetes
Currently open trials in the same condition.
- NCT05277558 — Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D) · recruiting
- NCT05015283 — Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission · NA · recruiting
- NCT05006508 — Prevention With the Health and Lifestyle Tool · NA · active not recruiting
- NCT04717050 — Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity · NA · active not recruiting
- NCT05220917 — Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study · active not recruiting
Other Université de Sherbrooke trials
Trials by the same sponsor.
- NCT07524764 — Female Reproductive Health in Canadian Armed Forces · not yet recruiting
- NCT07511842 — REST-Knee: A Pilot RCT of 72-Hour Knee Immobilization and Pain Outcomes · NA · recruiting
- NCT07360587 — Thyroid Artery Embolization for the Treatment of Compressive Goiters. · NA · recruiting
- NCT07396857 — The Role of EDHFs on Blood Pressure Following a Bout of Prolonged Sitting · NA · recruiting
- NCT07122531 — Recovery With Exogenous Ketones and Antipsychotics · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03298009 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Université de Sherbrooke
- Last refreshed: 13 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03298009.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing